HOME >> BIOLOGY >> NEWS
Mayo Clinic researchers enhance safety and effectiveness of therapeutic virus that fights cancer

Rochester, Minn. -- Mayo Clinic researchers working with colleagues in Germany have devised a much-needed multilevel safety feature for viruses used to treat cancer. In the process of making cancer-killing viruses more specific to cancer tumor cells, they report having improved the therapeutic effectiveness of viruses. They did this by engineering a modified measles virus that turns on only in the presence of secretions specific to malignant cancer cells.

In effect, the Mayo Clinic virus makeover uses proteins secreted by cancer cells as the unique key to the virus' ignition. Their report on the topic appears in the Aug. 1 edition of Cancer Research (http://cancerres.aacrjournals.org).

The investigation was performed in laboratory mice that were transplanted with a human cancer. The process is still experimental -- and thus, years away from clinical use in humans. However, the Mayo results may be immediately useful in designing improved cancer treatments for humans. "Our work shows that oncolytic measles virus particle activation can be made dependent on substances secreted by cancer cells, and this enhances safety," explains Roberto Cattaneo, Ph.D., lead researcher on the Mayo team. "By doing this, our study broadens the safeguarding strategies possible to tightly restrict the targeted virus to cancer cells."

Significance of the Mayo Clinic Research
The Mayo researchers say their contribution is a key advance because it provides a method of designing a therapeutic virus that is safe, stable and that reliably targets and kills cancer cells. Importantly, it appears to greatly reduce the possibility that the virus would erroneously turn on and harm the patient by causing unintended infection.

As such, the Mayo innovation of the cancer-activated virus is a helpful safety advance for the promising experimental field of "oncolytic virotherapy." The phrase refers to t
'"/>

Contact: Bob Nellis
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
1-Aug-2006


Page: 1 2

Related biology news :

1. 2007-2008 Genzyme/ACMGF Clinical Genetics Fellowship In Biochemical Genetics award winner announced
2. Scientists honored with Excellence in Clinical Research Award
3. Clinical trial data regarding NKTR-061 will be presented at ATS International Conference
4. NIH awards VBI, Mayo Clinic $2.4M to study chronic rhinosinusitis
5. Clinical trial for diabetic macular edema
6. The Parkinsons Institute to conduct Phase III Clinical Trial of creatine for Parkinsons disease
7. Research and program highlights of the 2007 Annual Clinical Genetics Meeting, March 21-25, 2007
8. Arizona State University and Mayo Clinic join forces to develop cancer vaccine
9. Marshfield Clinics electronic health record first to receive CCHIT certification
10. American College of Medical Genetics -- 2007 Annual Clinical Genetics Meeting Announcement
11. October MCP: A special issue on Clinical Proteomics

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/17/2017)... Florida , April 17, 2017 NXT-ID, ... technology company, announces the filing of its 2016 Annual Report on ... and Exchange Commission. ... on Form 10-K is available in the Investor Relations section of ... as on the SEC,s website at http://www.sec.gov . ...
(Date:4/11/2017)... Research and Markets has announced the addition ... their offering. ... tracking market to grow at a CAGR of 30.37% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
Breaking Biology News(10 mins):
(Date:5/18/2017)... ... May 18, 2017 , ... Dr. Ralph Mobbs of the ... Of Wales Private Hospital. The procedure was performed on a 46-year-old male patient ... treatments prior to undergoing surgery. , The AxioMed viscoelastic disc is a next-generation ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... with psychonneuroendocrine stress expertise, and further enhances its scientific power by providing ... A. Granger, Ph.D., has agreed to join the scientific advisory board. “We ...
(Date:5/18/2017)... Station, TX (PRWEB) , ... May 17, 2017 ... ... design and construction, announced today that their Chief Executive Officer, Maik Jornitz, was ... List. The UK publication’s Power List celebrates 100 individuals “involved in bettering the ...
(Date:5/16/2017)... ... May 16, 2017 , ... ... new ProxiMeta™ Hi-C metagenomic deconvolution service. ProxiMeta enables researchers to obtain complete, ... extraction—speeding research insights at lower cost. , “We’re very excited about the ...
Breaking Biology Technology:
Cached News: